Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay

Antiviral Research

Volumn 53, Issue 1, 2002, Pages 47-61

  Gubareva, Larisa V ^a   Webster, Robert G ^b,c   Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

BCX 1812; Cross resistance; Drug resistance; Neuraminidase inhibitors; Oseltamivir; Resistance monitoring; RWJ 270201; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ARGININE; CALCIUM; DIMETHYL SULFOXIDE; EDETIC ACID; LYSINE; PERAMIVIR; ZANAMIVIR;

ANIMAL CELL; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; ENZYME ASSAY; ENZYME INHIBITION; INFLUENZA VIRUS; MUTANT; NONHUMAN; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS RESISTANCE;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; DOGS; DRUG RESISTANCE, VIRAL; EDETIC ACID; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; OSELTAMIVIR; PYRANS; SIALIC ACIDS; ZANAMIVIR;

INFLUENZA VIRUS;

EID: 0036027825     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00192-9     Document Type: Article

References (44)

1. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design
2. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor RWJ-270201
3. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir
4. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
5. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
6. A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: Determination of molecular size and subunit composition of the active site
7. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid
8. Calcium is needed for the thermostability of influenza B virus neuraminidase
9. Development of a sensitive chemiluminescent neuraminidase assay for the detection of influenza virus susceptibility to zanamivir
10. Influenza virus sialidase: Effect of calcium on steady-state kinetic parameters
11. Neuraminidase: Enzyme and antigen
12. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase
13. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
14. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
15. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
16. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
17. Influenza virus neuraminidase inhibitors
18. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
19. Resistance of influenza A viruses to amantadine and rimantadine
20. Amantadine and rimantadine- Clinical aspects
21. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
22. Inhaled zanamivir for the prevention of influenza in families
23. Oral oseltamivir in human experimental influenza B infection
24. Assays for antiviral drug resistance
25. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism
26. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071
27. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors
28. Resistance of influenza viruses to neuraminidase inhibitors
29. The cytoplasmic tail of influenza A virus neuraminidase (NA) affects NA incorporation into virions, virion morphology and virulence in mice but is not essential for virus replication
30. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of action
31. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate
32. Substrate, inhibitor or antibody stabilizes the Glu 119 Gly mutant influenza virus nueraminidase
33. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201
34. Cyclopentane neuraminidsae inhibitors with potent in vitro anti-influenza virus activities
35. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en
36. Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: Evidence for virus-specific regulation of the pH of glycoprotein transport vesicles
37. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
38. Monitoring of viral susceptibility: New challenges with the develoment of influenza NA inhibitors
39. Characterization of an influenza A virus variant selected in vitro in the presence of the neuraminidase inhibitor GS4071
40. Studies on the mechanism by which mutations at His274 alter sensitivity of influenza A virus neuraminidase type 1 to GS4071 and zanamivir
41. Oral oseltamivir treatment of influenza in children
42. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
43. Position statement: Global neuraminidase inhibitor susceptibility network